October 21, 2016

ORI Finds Former PostDoc Fellow Engaged in Research Misconduct

Andrew R. Cullinane, Ph.D., National Institutes of Health:  Based on Respondent’s admission, an assessment conducted by the National Institutes of Health (NIH), and analysis conducted by ORI in its oversight review, ORI found that Dr. Andrew R. Cullinane, former postdoctoral fellow, Medical Genetics Branch, National Human Genome Research Institute (NHGRI), NIH, engaged in research misconduct…


July 5, 2016

A Top N.Y.U. Researcher Dismissed from Research Study

Alexander Neumeister, M.D., former head of the molecular imaging program at New York University (NYU) School of Medicine, conducted psychiatric research without providing appropriate oversight, states a Feb. 6 warning letter issued by the Food and Drug Administration (FDA), which cited a host of problems uncovered in two protocols during an inspection from July 16-Aug….


June 20, 2016

Misconduct: Lessons from Researcher Rehab

Please follow link for Full Article: http://www.nature.com/news/misconduct-lessons-from-researcher-rehab-1.20029


May 26, 2016

ORI Finds Investigator Committed Misconduct at Two Institutions

ORI Finds Investigator Committed Misconduct at Two Institutions The HHS Office of Research Integrity (ORI) has entered into a voluntary settlement agreement calling for the supervision of a researcher found to have committed misconduct at two different universities over a six-year period. In a May 24 notice on its website, ORI said Ricky Malhotra committed…


May 12, 2016

ORI Finds Two Committed Research Misconduct

A researcher has agreed to a five-year debarment for misconduct while another’s work, if involving Public Health Service (PHS) support, will be supervised for three years, according to the HHS Office of Research Integrity (ORI). The debarment was agreed to by John Pastorino, an associate professor in the Department of Molecular Biology at Rowan University…


March 21, 2016

FDA: Accept Human-focused Preclinical Tests to Improve Drug Safety

Patient deaths halted at least two pharmaceutical clinical trials in the last two months. The good news is, Robert Califf, M.D., who was confirmed by the Senate last week as commissioner of the Food and Drug Administration, has an opportunity to address this issue. In his new role, Dr. Califf is in a position to…


January 25, 2016

New FOA for Research on Research Integrity (Phase I)

The purpose of this Funding Opportunity Announcement (FOA) is to foster innovative approaches to empirical research on societal, organizational, group, and individual factors that affect, both positively and negatively, integrity in research. Integrity is defined as the use of honest and verifiable methods in proposing, performing, and evaluating research and reporting research results with particular…


December 10, 2015

Zafgen’s Beloranib IND gets complete clinical hold after second death

Zafgen, a Boston-based biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, has received verbal notice from the FDA that its beloranib investigational new drug (IND) application has been placed on complete clinical hold, affecting the ongoing open label extension (OLE) portion of the pivotal…


Misconduct Found in 11 Papers Published Over Nine-Year Period

  Girija Dasmahapatra, a former instructor in the Department of Medicine at Virginia Commonwealth University (VCU), committed research misconduct in 11 papers published from 2005 to 2014. Dasmahapatra “falsified and/or fabricated data by reporting the results of Western blot experiments and mouse imaging experiments that examined interactions between multiple histone deacetylase and/or proteasome inhibitors in…


November 16, 2015

ORI Case Summary – Potti, Anil

Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Anil Potti, M.D., Duke University School of Medicine:  Based on the reports of investigations conducted by Duke University School of Medicine (Duke) and additional analysis conducted by ORI in its oversight review, ORI found that Dr….


Next page